Abstract:

Objective To investigate the clinical characteristics of the pulmonary tuberculosis（PTB）with type 2 diabetes（T2DM）during treatment with metformin（MET）so as to provide reference for clinical treatment strategies. Methods The clinical data of 955 T2DM accompanied by primary PTB from January 2013 to January 2018 in our hospital were retrospectively analyzed. Of them，206 patients who had received the therapy with MET for more than three months before primary diagnosis with PTB were assigned into the observation group（MET group）and the rest 749 who had not received the therapy with MET for more than three months before primary diagnosis with PTB at the same period into the control group（NON⁃MET group）. Results There were no statistical differences in the standard level of HbA1c < 7%（P = 0.703）between both the groups，and so it was with the secondary infection（P = 0.703）. However，the NLR level，lung lesion range and rate of cavity occurrence in the MET group were all significantly lower or smaller than those in the non⁃MET group（P = 0.021，P = 0.045 and P = 0.039，respectively）. The rate of cavity occurrence among the patients with HbA1c < 7% was lower（P < 0.001） and the lung lesion range in the MET group was smaller（P = 0.042）. Conclusion T2DM patients with PTB treated with MET have a lower level of NLR，smaller range of lung lesions and lower rate of cavity occurrence. For those patients with HbA1c < 7%，the range of lung lesions is smaller.

Key words:

metformin, type 2 diabetes mellitus, pulmonary tuberculosis, infection, neutrophil? to?lymphocyte ratio